DOCSLIB.ORG

ICD10 Diagnosis Codes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ICD10 Diagnoses FY2020 AHD.com A020 Salmonella enteritis A4150 Gram-negative sepsis, unspecified B004 Herpesviral encephalitis A040 Enteropathogenic Escherichia coli A4151 Sepsis due to Escherichia coli [E. coli] B0089 Other herpesviral infection infection A4152 Sepsis due to Pseudomonas B009 Herpesviral infection, unspecified A044 Other intestinal Escherichia coli infections A4153 Sepsis due to Serratia B019 Varicella without complication A045 Campylobacter enteritis A4159 Other Gram-negative sepsis B0229 Other postherpetic nervous system involvement A0471 Enterocolitis due to Clostridium A4181 Sepsis due to Enterococcus difficile, recurrent B0230 Zoster ocular disease, unspecified A4189 Other specified sepsis A0472 Enterocolitis d/t Clostridium difficile, B027 Disseminated zoster A419 Sepsis, unspecified organism not spcf as recur B028 Zoster with other complications A430 Pulmonary nocardiosis A048 Other specified bacterial intestinal B029 Zoster without complications infections A46 Erysipelas B1081 Human herpesvirus 6 infection A049 Bacterial intestinal infection, A480 Gas gangrene unspecified B159 Hepatitis A without hepatic coma A481 Legionnaires' disease A059 Bacterial foodborne intoxication, B1710 Acute hepatitis C without hepatic unspecified A4901 Methicillin suscep staph infection, coma unsp site A0811 Acute gastroenteropathy due to B178 Other specified acute viral hepatitis Norwalk agent A4902 Methicillin resis staph infection, unsp site B179 Acute viral hepatitis, unspecified A0839 Other viral enteritis A493 Mycoplasma infection, unspecified B181 Chronic viral hepatitis B without A084 Viral intestinal infection, unspecified site delta-agent A088 Other specified intestinal infections A498 Other bacterial infections of B182 Chronic viral hepatitis C unspecified site A09 Infectious gastroenteritis and colitis, B1910 Unspecified viral hepatitis B without unspecified A499 Bacterial infection, unspecified hepatic coma A150 Tuberculosis of lung A5216 Charcot's arthropathy (tabetic) B1920 Unspecified viral hepatitis C without hepatic coma A310 Pulmonary mycobacterial infection A523 Neurosyphilis, unspecified B199 Unspecified viral hepatitis without A312 Dissem mycobacterium avium- A528 Late syphilis, latent hepatic coma intracellulare complex (DMAC) A530 Latent syphilis, unspecified as early B20 Human immunodeficiency virus A318 Other mycobacterial infections or late [HIV] disease A319 Mycobacterial infection, unspecified A539 Syphilis, unspecified B250 Cytomegaloviral pneumonitis A400 Sepsis due to streptococcus, group A A599 Trichomoniasis, unspecified B258 Other cytomegaloviral diseases A401 Sepsis due to streptococcus, group B A6000 Herpesviral infection of urogenital B259 Cytomegaloviral disease, unspecified system, unspecified A403 Sepsis due to Streptococcus B2700 Gammaherpesviral mononucleosis pneumoniae A6004 Herpesviral vulvovaginitis without complication A408 Other streptococcal sepsis A630 Anogenital (venereal) warts B2790 Infectious mononucleosis, unspecified without complication A409 Streptococcal sepsis, unspecified A6920 Lyme disease, unspecified B338 Other specified viral diseases A4101 Sepsis due to Methicillin susceptible A759 Typhus fever, unspecified Staphylococcus aureus B341 Enterovirus infection, unspecified A7740 Ehrlichiosis, unspecified A4102 Sepsis due to Methicillin resistant B342 Coronavirus infection, unspecified Staphylococcus aureus A7749 Other ehrlichiosis B348 Other viral infections of unspecified A411 Sepsis due to other specified A86 Unspecified viral encephalitis site staphylococcus A938 Other specified arthropod-borne B349 Viral infection, unspecified A412 Sepsis due to unspecified viral fevers staphylococcus B351 Tinea unguium B001 Herpesviral vesicular dermatitis A413 Sepsis due to Hemophilus influenzae B353 Tinea pedis B002 Herpesviral gingivostomatitis and A414 Sepsis due to anaerobes pharyngotonsillitis ICD10 Diagnoses FY2020 AHD.com B354 Tinea corporis B852 Pediculosis, unspecified B9681 Helicobacter pylori as the cause of diseases classd elswhr B356 Tinea cruris B853 Phthiriasis B9689 Oth bacterial agents as the cause of B359 Dermatophytosis, unspecified B86 Scabies diseases classd elswhr B368 Other specified superficial mycoses B888 Other specified infestations B970 Adenovirus as the cause of diseases classified elsewhere B369 Superficial mycosis, unspecified B91 Sequelae of poliomyelitis B9710 Unsp enterovirus as the cause of B370 Candidal stomatitis B942 Sequelae of viral hepatitis diseases classd elswhr B371 Pulmonary candidiasis B948 Sequelae of oth infectious and B9719 Oth enterovirus as the cause of parasitic diseases B372 Candidiasis of skin and nail diseases classd elswhr B950 Streptococcus, group A, causing B9729 Oth coronavirus as the cause of B373 Candidiasis of vulva and vagina diseases classd elswhr diseases classd elswhr B3741 Candidal cystitis and urethritis B951 Streptococcus, group B, causing B974 Respiratory syncytial virus causing diseases classd elswhr B3749 Other urogenital candidiasis diseases classd elswhr B952 Enterococcus as the cause of B377 Candidal sepsis B9781 Human metapneumovirus as the diseases classified elsewhere cause of diseases classd elswhr B3781 Candidal esophagitis B953 Streptococcus pneumoniae causing B9789 Oth viral agents as the cause of diseases classd elswhr B3789 Other sites of candidiasis diseases classd elswhr B954 Oth streptococcus as the cause of B379 Candidiasis, unspecified B998 Other infectious disease diseases classd elswhr B380 Acute pulmonary B999 Unspecified infectious disease coccidioidomycosis B955 Unsp streptococcus as the cause of diseases classd elswhr C01 Malignant neoplasm of base of B381 Chronic pulmonary tongue coccidioidomycosis B9561 Methicillin suscep staph infct causing dis classd elswhr C021 Malignant neoplasm of border of B382 Pulmonary coccidioidomycosis, tongue unspecified B9562 Methicillin resis staph infct causing diseases classd elswhr C028 Malignant neoplasm of overlapping B384 Coccidioidomycosis meningitis sites of tongue B957 Oth staphylococcus as the cause of B387 Disseminated coccidioidomycosis diseases classd elswhr C029 Malignant neoplasm of tongue, unspecified B389 Coccidioidomycosis, unspecified B958 Unsp staphylococcus as the cause of diseases classd elswhr C031 Malignant neoplasm of lower gum B399 Histoplasmosis, unspecified B960 Mycoplasma pneumoniae as the C039 Malignant neoplasm of gum, B440 Invasive pulmonary aspergillosis cause of diseases classd elswhr unspecified B441 Other pulmonary aspergillosis B961 Klebsiella pneumoniae as the cause C049 Malignant neoplasm of floor of of diseases classd elswhr B4481 Allergic bronchopulmonary mouth, unspecified aspergillosis B9620 Unsp Escherichia coli as the cause of C060 Malignant neoplasm of cheek diseases classd elswhr B4489 Other forms of aspergillosis mucosa B9622 Oth shiga toxin E coli [STEC] causing B449 Aspergillosis, unspecified C069 Malignant neoplasm of mouth, diseases classd elswhr unspecified B450 Pulmonary cryptococcosis B9629 Oth Escherichia coli as the cause of C07 Malignant neoplasm of parotid B451 Cerebral cryptococcosis diseases classd elswhr gland B457 Disseminated cryptococcosis B963 Hemophilus influenzae as the cause C090 Malignant neoplasm of tonsillar of diseases classd elswhr fossa B460 Pulmonary mucormycosis B964 Proteus (mirabilis) (morganii) C099 Malignant neoplasm of tonsil, B488 Other specified mycoses causing dis classd elswhr unspecified B49 Unspecified mycosis B965 Pseudomonas (mallei) causing C109 Malignant neoplasm of oropharynx, diseases classd elswhr unspecified B589 Toxoplasmosis, unspecified B966 Bacteroides fragilis as the cause of C119 Malignant neoplasm of B59 Pneumocystosis diseases classd elswhr nasopharynx, unspecified B600 Babesiosis ICD10 Diagnoses FY2020 AHD.com C139 Malignant neoplasm of C227 Other specified carcinomas of liver C3431 Malignant neoplasm of lower lobe, hypopharynx, unspecified right bronchus or lung C228 Malignant neoplasm of liver, C140 Malignant neoplasm of pharynx, primary, unspecified as to type C3432 Malignant neoplasm of lower lobe, unspecified left bronchus or lung C229 Malig neoplasm of liver, not C154 Malignant neoplasm of middle third specified as primary or sec C3480 Malignant neoplasm of ovrlp sites of of esophagus unsp bronchus and lung C23 Malignant neoplasm of gallbladder C155 Malignant neoplasm of lower third C3481 Malignant neoplasm of ovrlp sites of of esophagus C240 Malignant neoplasm of extrahepatic right bronchus and lung bile duct C159 Malignant neoplasm of esophagus, C3482 Malignant neoplasm of ovrlp sites of unspecified C241 Malignant neoplasm of ampulla of left bronchus and lung Vater C160 Malignant neoplasm of cardia C3490 Malignant neoplasm of unsp part of C249 Malignant neoplasm of biliary tract, unsp bronchus or lung C162 Malignant neoplasm of body of unspecified stomach C3491 Malignant neoplasm of unsp part of C250 Malignant neoplasm of head of right bronchus or lung C163 Malignant neoplasm of pyloric pancreas antrum C3492 Malignant neoplasm of unsp part of C251 Malignant neoplasm of body of left bronchus or lung C168 Malignant neoplasm of overlapping pancreas sites of stomach C37 Malignant neoplasm of thymus C252 Malignant neoplasm of tail of C169 Malignant neoplasm of stomach, pancreas C4021 Malignant neoplasm of long bones unspecified of right lower limb C253 Malignant neoplasm of pancreatic C170 Malignant neoplasm of duodenum duct C4022 Malignant neoplasm of long bones of left lower limb C179 Malignant neoplasm of small C254 Malignant neoplasm
Recommended publications
  • ICD10 Diagnoses FY2018 AHD.Com

    ICD10 Diagnoses FY2018 AHD.Com

    ICD10 Diagnoses FY2018 AHD.com A020 Salmonella enteritis A5217 General paresis B372 Candidiasis of skin and nail A040 Enteropathogenic Escherichia coli A523 Neurosyphilis, unspecified B373 Candidiasis of vulva and vagina infection A528 Late syphilis, latent B3741 Candidal cystitis and urethritis A044 Other intestinal Escherichia coli A530 Latent syphilis, unspecified as early or B3749 Other urogenital candidiasis infections late B376 Candidal endocarditis A045 Campylobacter enteritis A539 Syphilis, unspecified B377 Candidal sepsis A046 Enteritis due to Yersinia enterocolitica A599 Trichomoniasis, unspecified B3781 Candidal esophagitis A047 Enterocolitis due to Clostridium difficile A6000 Herpesviral infection of urogenital B3789 Other sites of candidiasis A048 Other specified bacterial intestinal system, unspecified B379 Candidiasis, unspecified infections A6002 Herpesviral infection of other male B380 Acute pulmonary coccidioidomycosis A049 Bacterial intestinal infection, genital organs B381 Chronic pulmonary coccidioidomycosis unspecified A630 Anogenital (venereal) warts B382 Pulmonary coccidioidomycosis, A059 Bacterial foodborne intoxication, A6920 Lyme disease, unspecified unspecified unspecified A7740 Ehrlichiosis, unspecified B387 Disseminated coccidioidomycosis A080 Rotaviral enteritis A7749 Other ehrlichiosis B389 Coccidioidomycosis, unspecified A0811 Acute gastroenteropathy due to A879 Viral meningitis, unspecified B399 Histoplasmosis, unspecified Norwalk agent A938 Other specified arthropod-borne viral B440 Invasive pulmonary
  • Latent Tuberculosis Infection

    Latent Tuberculosis Infection

    © National HIV Curriculum PDF created September 27, 2021, 4:20 am Latent Tuberculosis Infection This is a PDF version of the following document: Module 4: Co-Occurring Conditions Lesson 1: Latent Tuberculosis Infection You can always find the most up to date version of this document at https://www.hiv.uw.edu/go/co-occurring-conditions/latent-tuberculosis/core-concept/all. Background Epidemiology of Tuberculosis in the United States Although the incidence of tuberculosis in the United States has substantially decreased since the early 1990s (Figure 1), tuberculosis continues to occur at a significant rate among certain populations, including persons from tuberculosis-endemic settings, individual in correctional facilities, persons experiencing homelessness, persons who use drugs, and individuals with HIV.[1,2] In recent years, the majority of tuberculosis cases in the United States were among the persons who were non-U.S.-born (71% in 2019), with an incidence rate approximately 16 times higher than among persons born in the United States (Figure 2).[2] Cases of tuberculosis in the United States have occurred at higher rates among persons who are Asian, Hispanic/Latino, or Black/African American (Figure 3).[1,2] In the general United States population, the prevalence of latent tuberculosis infection (LTBI) is estimated between 3.4 to 5.8%, based on the 2011 and 2012 National Health and Nutrition Examination Survey (NHANES).[3,4] Another study estimated LTBI prevalence within the United States at 3.1%, which corresponds to 8.9 million persons
  • Tuberculosis Policy and Procedure Manual 2012

    Tuberculosis Policy and Procedure Manual 2012

    Tuberculosis Policy and Procedure Manual 2012 Georgia Department of Public Health Division of Health Protection Tuberculosis Program http://www.health.state.ga.us Georgia Tuberculosis Policy and Procedure Manual 2012 1 [THIS PAGE INTENTIONALLY LEFT BLANK] Georgia Tuberculosis Policy and Procedure Manual 2012 2 TABLE OF CONTENTS INTRODUCTION .................................................................................................................................. 5 RESPONSIBILITIES FOR TB CONTROL .......................................................................................... 7 MISSION ............................................................................................................................................ 7 Legislative authority ........................................................................................................................... 7 RESPONSIBILITY OF THE STATE TB PROGRAM ..................................................................... 7 RESPONSIBILITY OF THE DISTRICT TB PROGRAM ............................................................... 9 RESPONSIBILITY OF THE COUNTY TB PROGRAM ............................................................... 12 TUBERCULOSIS MEDICAL RECORDS .......................................................................................... 15 Retention of Medical Records .......................................................................................................... 15 SURVEILLANCE ...............................................................................................................................
  • Neuropsychological Testing

    Neuropsychological Testing

    Medical Coverage Policy Effective Date ............................................. 8/15/2021 Next Review Date ....................................... 8/15/2022 Coverage Policy Number .................................. 0258 Neuropsychological Testing Table of Contents Related Coverage Resources Overview .............................................................. 1 Attention-Deficit/Hyperactivity Disorder: Assessment Coverage Policy ................................................... 1 and Treatment General Background ............................................ 2 Autism Spectrum Disorder/Pervasive Developmental Medicare Coverage Determinations .................. 15 Disorders: Assessment and Treatment Coding/Billing Information .................................. 16 Cognitive Rehabilitation Lyme Disease Treatment— Antibiotic Treatment References ........................................................ 28 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary
  • Academy of Medical Sciences of Ukraine L. V. Gromashevskiy

    Academy of Medical Sciences of Ukraine L. V. Gromashevskiy

    Academy of Medical Sciences of Ukraine L. V. Gromashevskiy Institute of Epidemiology and Infektious Diseases Panasiuk Olena Leonidivna ETHIOPATHOGENETIC THERAPY OF HERPES VIRUS INFECTION WITH THE USE OF PROTEFLAZID 14.01.13 — Infektious Diseases Kyiv — 2007 TABLE OF CONTENTS LIST OF ABBREVIATIONS USED INTRODUCTION CHAPTER 1 PRESSING ISSUES OF TREATMENT OF HERPES VIRUS INFECTIONS 1.2. Main principles of treatment of patients with herpes virus infections CHAPTER 2 MATERIALS AND STUDY METHODS 2.1. Characteristic of examined patients 2.2. Characteristic of study drug and treatment methods 2.3. Study design 2.3.1. Subjects enrollment and discontinuation criteria 2.3.2. Principles and algorithm of subjects grouping 2.3.3. Assessment of therapy efficacy 2.4. Study methods 2.4.1. Clinical method 2.4.2. Special study methods 2.4.3. Statistical method CHAPTER 3 ETHIOPATHOGENETIC THERAPY OF HERPES VIRUS INFECTION WITH THE USE OF PROTEFLAZID 3.1. Clinical efficacy of Proteflazid 3.2. Adverse effects of therapy with Proteflazid 3.3. Interferon inducing and immunomodulatory activity of Proteflazid in subjects with herpes virus infection 3.3.1. Immunomodulatory activity of Proteflazid 3.3.2. Interferon inducing properties of Proteflazid CHAPTER 4 LONG-TERM RESULTS OF TREATMENT OF HERPES VIRUS INFECTION 4.1. Anti-relapse efficacy of Proteflazid CONCLUSIONS PRACTICAL GUIDELINES REFERENCES List of abbreviations used NK (CD16) — natural killer cells NSE — neurospecific enolase ME — meningoencerebritis ANAD — acyclic nucleoside antiviral drugs AB — antibody
  • Latent Tuberculosis Infection

    Latent Tuberculosis Infection

    Latent tuberculosis infection Scaling up programmatic management of LTBI, a critical action to achieve the WHO End TB Strategy targets KEY FACTS . Latent tuberculosis infection (LTBI) is a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB. About one-third of the world's population has latent TB, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit the disease. Persons with LTBI do not have active TB disease but may develop it in the near or in the remote future, a process called TB reactivation. It is critical to prevent the development of active disease by providing preventive treatment to those who are at high risk. People living with HIV and children less than 5 years who are household contacts of pulmonary TB cases are key target risk groups globally. In 2015, over 900,000 people living with HIV and around 90,000 child household TB contacts less than 5 years old were provided with preventive treatment. LTBI DIAGNOSIS 2-3 billion persons with LTBI globally Persons with LTBI have negative bacteriological tests: the diagnosis is based on a positive result of either a skin (tuberculin skin test, TST) or blood (Interferon-gamma About one in three persons release assay, IGRA) test indicating an immune response to M.tuberculosis. However, these tests have limitations as they cannot distinguish between latent infection with viable microorganisms and healed/treated infections; they also do not predict who will progress to active TB. WHO recommendations for the management of LTBI, by country group LTBI TREATMENT SCALE-UP http://www.who.int/tb/chLTBI can be effectively treated to prevent progression Systematic diagnosis and treatment of LTBI is to active TB, thus resulting in a substantial benefit for part of the new End TB strategy and achieving the individual.
  • SNF Mobility Model: ICD-10 HCC Crosswalk, V. 3.0.1

    SNF Mobility Model: ICD-10 HCC Crosswalk, V. 3.0.1

    The mapping below corresponds to NQF #2634 and NQF #2636. HCC # ICD-10 Code ICD-10 Code Category This is a filter ceThis is a filter cellThis is a filter cell 3 A0101 Typhoid meningitis 3 A0221 Salmonella meningitis 3 A066 Amebic brain abscess 3 A170 Tuberculous meningitis 3 A171 Meningeal tuberculoma 3 A1781 Tuberculoma of brain and spinal cord 3 A1782 Tuberculous meningoencephalitis 3 A1783 Tuberculous neuritis 3 A1789 Other tuberculosis of nervous system 3 A179 Tuberculosis of nervous system, unspecified 3 A203 Plague meningitis 3 A2781 Aseptic meningitis in leptospirosis 3 A3211 Listerial meningitis 3 A3212 Listerial meningoencephalitis 3 A34 Obstetrical tetanus 3 A35 Other tetanus 3 A390 Meningococcal meningitis 3 A3981 Meningococcal encephalitis 3 A4281 Actinomycotic meningitis 3 A4282 Actinomycotic encephalitis 3 A5040 Late congenital neurosyphilis, unspecified 3 A5041 Late congenital syphilitic meningitis 3 A5042 Late congenital syphilitic encephalitis 3 A5043 Late congenital syphilitic polyneuropathy 3 A5044 Late congenital syphilitic optic nerve atrophy 3 A5045 Juvenile general paresis 3 A5049 Other late congenital neurosyphilis 3 A5141 Secondary syphilitic meningitis 3 A5210 Symptomatic neurosyphilis, unspecified 3 A5211 Tabes dorsalis 3 A5212 Other cerebrospinal syphilis 3 A5213 Late syphilitic meningitis 3 A5214 Late syphilitic encephalitis 3 A5215 Late syphilitic neuropathy 3 A5216 Charcot's arthropathy (tabetic) 3 A5217 General paresis 3 A5219 Other symptomatic neurosyphilis 3 A522 Asymptomatic neurosyphilis 3 A523 Neurosyphilis,
  • 30-Year Trends in Admission

    30-Year Trends in Admission

    Iro, M. A., Sadarangani, M., Goldacre, R., Nickless, A., Pollard, A., & Goldacre, M. J. (2017). 30-year trends in admission rates for encephalitis in children in England and effect of improved diagnostics and measles-mumps-rubella vaccination: a population-based observational study. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(17)30114-7 Peer reviewed version License (if available): CC BY-NC-ND Link to published version (if available): 10.1016/S1473-3099(17)30114-7 Link to publication record in Explore Bristol Research PDF-document This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://doi.org/10.1016/S1473-3099(17)30114-7 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Thirty-year trends in admission rates for childhood encephalitis in England and impact of improved diagnostics and measles and mumps vaccination– a population based observational study Mildred A Iro (MBBS) 1, Manish Sadarangani (DPhil) 1,2, Raphael Goldacre (MSc)3, Alecia Nickless (MSc) 4, Prof Andrew J Pollard* (FMedSci) 1, Prof Michael J Goldacre* (FFPH) 3 1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical
  • Supplementary Appendix

    Supplementary Appendix

    Supplementary appendix Sipilä PN, Heikkilä N, Lindbohm JV, Hakulinen C, Vahtera J, Elovainio M, Suominen S, Väänänen A, Koskinen A, Nyberg ST, Pentti J, Strandberg TE, Kivimäki M. Hospital-treated infectious diseases and the risk of incident dementia: multicohort study with replication in the UK Biobank CONTENTS eFigure 1. Selection of participants in the study............................................................................... 2 eMethods 1. Study cohorts and data collection ................................................................................ 3 The Finnish Public Sector study (FPS)......................................................................................... 3 The Health and Social Support study (HeSSup) ........................................................................... 4 The Still Working study (STW) ................................................................................................... 5 The UK Biobank ......................................................................................................................... 5 eMethods 2. Proportionality of hazards ........................................................................................... 7 eFigure 2. Visualisation of hazard ratios over time using exponentiated scaled Schoenfeld residuals ....................................................................................................................................................... 8 eFigure 3. Dementia follow-up .....................................................................................................
  • Diagnosis of Tuberculosis in Adults and Children David M

    Diagnosis of Tuberculosis in Adults and Children David M

    Clinical Infectious Diseases IDSA GUIDELINE Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children David M. Lewinsohn,1,a Michael K. Leonard,2,a Philip A. LoBue,3,a David L. Cohn,4 Charles L. Daley,5 Ed Desmond,6 Joseph Keane,7 Deborah A. Lewinsohn,1 Ann M. Loeffler,8 Gerald H. Mazurek,3 Richard J. O’Brien,9 Madhukar Pai,10 Luca Richeldi,11 Max Salfinger,12 Thomas M. Shinnick,3 Timothy R. Sterling,13 David M. Warshauer,14 and Gail L. Woods15 1Oregon Health & Science University, Portland, Oregon, 2Emory University School of Medicine and 3Centers for Disease Control and Prevention, Atlanta, Georgia, 4Denver Public Health Department, Denver, Colorado, 5National Jewish Health and the University of Colorado Denver, and 6California Department of Public Health, Richmond; 7St James’s Hospital, Dublin, Ireland; 8Francis J. Curry International TB Center, San Francisco, California; 9Foundation for Innovative New Diagnostics, Geneva, Switzerland; 10McGill University and McGill International TB Centre, Montreal, Canada; 11University of Southampton, United Kingdom; 12National Jewish Health, Denver, Colorado, 13Vanderbilt University School of Medicine, Vanderbilt Institute for Global Health, Nashville, Tennessee, 14Wisconsin State Laboratory of Hygiene, Madison, and 15University of Arkansas for Medical Sciences, Little Rock Downloaded from Background. Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of disease (tuber- culosis disease) or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). Tuberculosis disease is a leading cause of infectious disease morbidity and mortality worldwide, yet many questions related to its diagnosis remain.
  • Latent Tuberculosis

    Latent Tuberculosis

    Editorial Latent tuberculosis Sankalp Yadav1,*, Gautam Rawal2 1General Duty Medical Officer- II, Dept. of Medicine & TB, Chest Clinic Moti Nagar, North Delhi Municipal Corporation, New Delhi, 2Attending Consultant, Dept. of Respiratory Intensive Care, Max Super Specialty Hospital, Saket, New Delhi *Corresponding Author: Email: [email protected] India is having a number of public health aforementioned serodiagnostic tests, even in cases problems[1]. Tuberculosis (TB) and HIV are some who have no clinical signs or symptoms of TB and of the most common public health issues that need thus resulting in a higher chance of the development to be addressed and are the top two causes of the of drug resistance in such patients[6]. Also, these deaths due to infectious disease[1]. TB is caused by treatments often leads to the development of side an airborne infection by the Mycobacterium effects in the patients due to antitubercular drugs[7]. tuberculosis[1-3]. Also, India is a high TB burden Besides, once diagnosed as latent TB there is country with a very high number of morbidity and no consensus on the management[6]. There are no mortality due to TB[1,3,4]. Latent tuberculosis large scale studies available to treat latent TB. infection (LTBI) is a state of persistent immune Presently, the treatment may vary from the use of response to stimulation by Mycobacterium one or two drugs over a highly variable time tuberculosis antigens without evidence of clinically duration[5-7]. Some studies have even advocated the manifested active TB[5]. The presence of latent TB use of certain drugs like Moxifloxacin which are in India is well reported and experienced by commonly used in DR-TB cases[6].
  • Testing for Diagnosis of Active Or Latent Tuberculosis

    Testing for Diagnosis of Active Or Latent Tuberculosis

    Corporate Medical Policy Testing for Diagnosis of Active or Latent Tuberculosis AHS – G2063 File Name: testing_for_diagnosis_of_active_or_latent_tuberculosis Origination: 4/1/2019 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Description Infection by Mycobacterium tuberculosis (Mtb) results in a wide range of clinical presentations dependent upon the site of infection from classic signs and symptoms of pulmonary disease (cough >2 to 3 weeks' duration, lymphadenopathy, fevers, night sweats, weight loss) to silent infection with a complete absence of signs or symptoms(Lewinsohn et al., 2017). Culture of Mtb is the gold standard for diagnosis as it is the most sensitive and provides an isolate for drug susceptibility testing and species identification (Bernardo, 2019). Nucleic acid amplification tests (NAAT) use polymerase chain reactions (PCR) to enable sensitive detection and identification of low density infections ( Pai, Flores, Hubbard, Riley, & Colford, 2004). Interferon-gamma release assays (IGRAs) are blood tests of cell-mediated immune response which measure T cell release of interferon (IFN)-gamma following stimulation by specific antigens such as Mycobacterium tuberculosis antigens (Lewinsohn et al., 2017; Dick Menzies, 2019) used to detect a cellular immune response to M. tuberculosis which would indicate latent tuberculosis infection (LTBI) (Pai et al., 2014). Scientific Background Tuberculosis (TB) continues to be a major public health threat globally, causing an estimated 10.0 million new cases and 1.5 million deaths from TB in 2018 (WHO, 2016, 2019), with the emergence of multidrug resistant strains only adding to the threat (Dheda et al., 2014). The lungs are the primary site of infection by Mtb and subsequent TB disease.